Figure 5. Intralesional injection with IL-7 and IL-15 in RFA-treated animals reduced CD11b+Gr1+ MDCS compared to untreated tumor-bearing mice.

FVBN202 transgenic mice were challenged with MMC and Balb/c mice were challenged with 4T1 tumors. Ten-fourteen days later, animals were treated with RFA, RFA + IL-7 and IL-15, or remained untreated. Naïve mice were used as controls. Animals were sacrificed 1−2 weeks later and their splenocytes were stained with FITC-CD11b and PEGr1 Abs. Percent double positive cells were analyzed on gated granulocyte regions. Representative data are presented from four mice per group.